Given that combination of ICIs and chemotherapy resulted in an ORR of 63.3%, median PFS of 11.0 months, and median OS of 20.3 months in BRAF V600E mutated patients in our study, we propose that the optimal sequence of the therapy regimen may be chemotherapy plus ICIs as the first-line therapy and then targeted therapy for BRAF V600E NSCLC patients. This evidence concerns the gene BRAF and non-small cell lung carcinoma.